PATIENT INFORMATION LEAFLET

Remifentanilo Noridem 5 mg powder for concentrate for injectable solution and for EFG infusion

Remifentanil hydrochloride

Read this leaflet carefully before you start using the medicine because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor, pharmacist or nurse.
• If you experience any side effects, consult your doctor, pharmacist or nurse, even if they are not listed in this leaflet. See section 4.

The name of your medicine isRemifentanilo Noridem5mgpowder for concentrate for injectable solution and for EFG infusion.

In the rest of this leaflet, your medicinewill be calledRemifentanilo Noridem.

1.What Remifentanilo Noridem is and what it is used for

2.What you need to know before you start using Remifentanilo Noridem

3.How to use Remifentanilo Noridem

4.Possible side effects

5.Storage of Remifentanilo Noridem

6.Contents of the pack and additional information

Remifentanilo Noridem contains a medication called remifentanilo thatbelongs to a group of medications called opioids.

Remifentanilo Noridem isused in combination with other medications called anesthetics:

• to help you fall asleepbeforea surgical operation
• to prevent you from feeling pain and keep you asleepduringa surgical operation

to keep you drowsy and prevent you from feeling pain while receiving treatment in an Intensive Care Unit.

Do not use Remifentanilo Noridem if:

• You are allergic (hypersensitive) to remifentanilo or to any of the other components of this medication (listed in section 6)
• You are allergic (hypersensitive) to any other medicationAnalgésico similar to fentanilo and related to the class of medications known as opiáceos

If you are not sure if you fall into any of the above cases, consult your doctor, pharmacist or healthcare professional before using Remifentanilo Noridem.

Warnings and precautions:

Consult your doctor or pharmacist before starting to useRemifentanilo Noridem if:

• You are allergic (hypersensitive) to any other opioid medication, such as morphine or codeine

• You are over 65 years old
• You are dehydrated or have lost a lot of blood
• You have not been feeling wellor have felt weak.
• You are overweight
• You or a family member have ever abused or had dependence on alcohol, prescription medications or illegal drugs (“addiction”)
• You are a smoker
• You have ever had mood disorders (depression, anxiety or personality disorder) or have been treated by a psychiatrist for other mental illnesses.

If you are not sure if you fall into any of the above cases, consult your doctor, pharmacist or healthcare professional before using Remifentanilo Noridem.

This medication contains remifentanilo which is an opioid. The repeated use of opioids can make the medication lose its effectiveness (become accustomed to its effect). It can also cause dependence and abuse, which in turn can cause a potentially fatal overdose. If you are concerned that you may become dependent on Remifentanilo Noridem, it is essential that you consult your doctor.

Occasionally, withdrawal reactions (e.g., rapid heartbeats, high blood pressure and agitation) have been reported after sudden discontinuation of treatment with this medication, especially when treatment was administered for more than 3 days (see also section 4. Possible side effects). If you experience these symptoms, your doctor may restart treatment with the medication and gradually reduce the dose.

Use of Remifentanilo Noridem with other medications

Inform your doctor or pharmacist if you are using or have used recently or may need to use other medications, even those obtained without a prescription and herbal medications. This is because Remifentanilo Noridem can interact with other medications causing adverse effects.

It is especially important to inform your doctor or pharmacist if you are taking:

• Blood pressure medications or heart problems medications, such as beta-blockers (including atenolol, metoprolol, carvedilol, propanololand bisoprolol) or calcium channel blockers (including amlodipino, diltiazem and nifedipino).
• Depression medications, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs). It is not recommended to use these medications at the same time as Remifentanilo Noridem, as they may increase the risk of serotonin syndrome, a potentially fatal disease.

The concomitant use of opioids and other medications used to treat epilepsy, nerve pain or anxiety (gabapentina and pregabalina) increases the risk of opioid overdose and respiratory depression, and may be potentially fatal.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or intend to become pregnant,consult your doctor before using this medication.

If you receive this medication during delivery or shortly before delivery, it may affect your baby's breathing. You and your baby will be monitored for signs of excessive sleepiness or difficulty breathing.

Driving and operating machinery

If you are hospitalized only during the day, your doctor will inform you how long to wait before leaving the hospital or driving vehicles. It may be hazardous to drive too soon after undergoing surgery.

This medication may affect your ability to drive because it can make you feel drowsy or dizzy.

• Do not drive while taking this medication until you know how it affects you.

Consult your doctor or pharmacist if you are unsure if you can drive safely while taking this medication.

Administration by Injection

This medication should never be administered by yourself. This medication will always be administered by qualified healthcare personnel.

Remifentanilo Noridem may be administered:

• as a single injection into a vein
• as a continuous infusion (drip) into a vein, if you need to receive the medication over a longer period of time.

The way you will receive the medication and the dose you will receive will depend on:

• your weight

• the type of operation you will undergo
• the level of pain expected from the operation
• the level of sedation that healthcare personnel deem most appropriate for you in the Intensive Care Unit.

The dose may vary from one patient to another.

If you use more Remifentanilo Noridem than you should

The effects of Remifentanilo Noridem are closely monitored throughout the operation and in intensive care. If you have received too much, appropriate measures will be taken promptly.

If you believe you have been given more Remifentanilo than you should have, consult your doctor or pharmacist immediately.

After surgery

Inform your doctor or healthcare personnel if you feel pain. If you experience pain after surgery, they may administer other pain relievers to alleviate it.

Like all medications, Remifentanilo Noridem may cause side effects, although not everyone will experience them. With this medication, the following side effects may occur.

Some people may be allergic to Remifentanilo.You must inform your doctor or healthcare staff immediately if you feel:

Rare(may affect up to 1 user in every 1,000)

• sudden onset of sneezing and chest pain or sensation of compression
• swelling of the eyelids, face, lips, mouth, or tongue
• urticaria with bumps or rash on any part of your body
• loss of consciousness.

Inform your doctoras soon as possibleif you feel any of the following side effects:

Very frequent(may affect more than 1 user in every 10)

• muscle stiffness
• low blood pressure
• nausea or vomiting

Frequent(may affect up to 1 user in every 10)

• slow heart rate
• shallow breathing or temporary cessation of breathing
• itching
• coughing

Infrequent(may affect up to 1 user in every 100)

• respiratory problems (hypoxia)
• constipation

Rare(may affect up to 1 user in every 1,000)

• allergic reactions
• cardiac arrest

Unknown(cannot be estimated from available data)

• physical need for remifentanilo (dependence) or need to increase doses over time to achieve the same effect (tolerance)
• seizures
• a type of irregular heart rhythm (atrioventricular block)
• irregular heartbeat (arrhythmia)
• withdrawal syndrome (may manifest with the following side effects: increased heart rate, hypertension, feeling of agitation or restlessness, nausea, vomiting, diarrhea, anxiety, chills, tremors, and sweating)

Other side effects that may occur when you wake up after anesthesia:

Frequent(may affect up to 1 user in every 10)

• chills
• increased blood pressure

Infrequent(may affect up to 1 user in every 100)

• pain

Rare(may affect up to 1 user in every 1,000)

• extreme feeling of calmness or drowsiness (sedation)

Reporting of side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for human use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.

Keep this medication out of the sight and reach of children.

Do not use Remifentanil Noridem after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.

Do not use the reconstituted product if you observe that the solution is not transparent, colorless and practically free of particles.

Do not conserve at a temperature above 25°C.Conserve the vial in its original packaging to protect it from light.

Once reconstituted, use Remifentanil Noridem immediately. The unused solution should not be thrown down the drain or in the trash. Your doctor or healthcare personnel will dispose of the unused medication. This will help protect the environment.

Composition of Remifentanil Noridem

• The active ingredient is remifentanil hydrochloride.
• The other components are glycine and hydrochloric acid (for pH adjustment).

Appearance of the product and contents of the container

Remifentanil Noridem is a white or almost white, lyophilized, sterile powder free of bacteria. This powder must be mixed with an appropriate fluid before injection. Once mixed, the resulting Remifentanil Noridem solution is transparent and colorless.

Remifentanil Noridem powder for concentrate for solution for injection or infusion is distributed in glass vials with bromobutyl rubber stoppers, which contain 1 mg of remifentanil (as remifentanil hydrochloride).

Each of these two concentrations of Remifentanil Noridem is distributed in carton containers with 5 and 10 vials.

Only some sizes of containers may be commercially available.

Holder of the marketing authorization and responsible manufacturer

Holder of the marketing authorization:Noridem Enterprises Ltd., Evagorou & Makariou, Mitsi Building 3, Office 115, 1065 Nicosia, Cyprus.

Manufacturer:DEMO S.A., 21st km National Road Athens-Lamia, 14568 Krioneri, Attica, Greece.

This medicinal product is authorized in the member states of the European Economic Area with the following names:

Last review date of this leaflet:05/2022.

The detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/

This information is intended exclusively for medical or healthcare professionals: Consult the complete prescribing information in the Product Technical File. The information provided in this section are the instructions for the preparation of Remifentanil Noridem before administration and the guidelines for the infusion rates of Remifentanil Noridem for controlled manual infusion. PREPARATION GUIDE for Remifentanil Noridem 1 mg Powder for Concentrate for Solution for Injection or Infusion Remifentanil Noridem is a sterile, lyophilized, endotoxin-free, preservative-free powder, white or almost white, which must be reconstituted before use. Remifentanil Noridem is available in glass vials containing 1 mg of remifentanil base. The vials should not be stored above 25°C. When reconstituted according to the recommendations, the Remifentanil Noridem solutions are transparent and colorless and contain 1 mg/ml of remifentanil base, in the form of remifentanil hydrochloride. Remifentanil Noridem should not be administered without additional dilution after reconstitution of the lyophilized powder. It is essential to read the entire content of this guide before preparing this medication. This information can also be found in sections 6.4 and 6.6 of the Product Technical File. Reconstitution of the lyophilized powder Remifentanil Noridem must be prepared for intravenous use by adding, as necessary, 1, 2, or 5 ml of diluent (see the list of diluents in "Additional Dilution") to obtain a reconstituted solution with a concentration of 1 mg/ml of remifentanil. This reconstituted solution is transparent, colorless, and practically free of particles. After reconstitution, visually inspect the product (if the container allows it) to determine the presence of particles, coloration, or deterioration of the container. Discard any solution in which these defects are observed. The reconstituted product is for single use only. Any unused material must be discarded. Additional Dilution Once reconstituted, Remifentanil Noridem should not be administered by controlled manual infusion without performing additional dilution to concentrations of 20 to 250 micrograms/ml (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for pediatric patients aged 1 year or more, when used for maintenance of anesthesia). The use of Remifentanil Noridem in pediatric patients under 18 years old for analgesia in intensive care unit patients with mechanical ventilation is not recommended. Once reconstituted, Remifentanil Noridem should not be administered by TCI infusion without additional dilution (the recommended dilution for TCI is 20 to 50 micrograms/ml). The chosen dilution depends on the technical capabilities of the infusion device and the patient's expected needs. To dilute, one of the IV fluids listed below must be used: Water for injection 5% glucose injection 5% glucose and 0.9% sodium chloride injection 0.9% sodium chloride injection 0.45% sodium chloride injection After dilution, visually inspect the product to ensure it is transparent, colorless, practically free of particles, and the container does not show deterioration. Discard any solution in which these defects are observed. Chemical and physical stability has been demonstrated for use over 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the storage times and conditions of the reconstituted solution, prior to use, are the responsibility of the user and are normally not to exceed 24 hours at 2-8°C, unless reconstitution/dilution has taken place under controlled and validated aseptic conditions. However, Remifentanil Noridem does not contain any antimicrobial preservative and, therefore, care must be taken to ensure the sterility of the prepared solutions, and the reconstituted product should be used promptly and any unused material discarded. Compatibility of Remifentanil Noridem with the following IV fluids has been demonstrated when administered through a central venous catheter: Ringer's lactate injection Ringer's lactate and 5% glucose injection Compatibility of Remifentanil Noridem with propofol has been demonstrated when administered through a central venous catheter. INFUSION RATE GUIDELINES The following tables provide recommendations on infusion rates of Remifentanil Noridem for controlled manual infusion: Table 1. Infusion rates (mL/kg/h) of Remifentanil Noridem powder for concentrate for solution for injection or infusion Infusion rate of the drug (micrograms/kg/min) Infusion rate of the infusion (mL/kg/h) for solutions of: 20 micrograms /mL 1 mg/50 mL 25 micrograms /mL 1 mg/40 mL 50 micrograms /mL 1 mg/20 mL 250 micrograms /mL 10 mg/40 mL 0.0125 0.038 0.03 0.015 Not recommended 0.025 0.075 0.06 0.03 Not recommended 0.05 0.15 0.12 0.06 0.012 0.075 0.23 0.18 0.09 0.018 0.1 0.3 0.24 0.12 0.024 0.15 0.45 0.36 0.18 0.036 0.2 0.6 0.48 0.24 0.048 Table 2. Infusion rates (mL/h) for a solution of 20 micrograms/mL of Remifentanil Noridem powder for concentrate for solution for injection or infusion Infusion rate (micrograms/kg/min) Patient body weight (kg) 5 10 20 30 40 50 60 0.0125 0.188 0.375 0.75 1.125 1.5 1.875 2.25 0.025 0.375 0.75 1.5 2.25 3.0 3.75 4.5 0.05 0.75 1.5 3.0 4.5 6.0 7.5 9.0 0.075 1.125 2.25 4.5 6.75 9.0 11.25 13.5 0.1 1.5 3.0 6.0 9.0 12.0 15.0 18.0 0.15 2.25 4.5 9.0 13.5 18.0 22.5 27.0 0.2 3.0 6.0 12.0 18.0 24.0 30.0 36.0 0.25 3.75 7.5 15.0 22.5 30.0 37.5 45.0 0.3 4.5 9.0 18.0 27.0 36.0 45.0 54.0 0.35 5.25 10.5 21.0 31.5 42.0 52.5 63.0 0.4 6.0 12.0 24.0 36.0 48.0 60.0 72.0 Table 3. Infusion rates (mL/h) for a solution of 25 micrograms/mL of Remifentanil Noridem powder for concentrate for solution for injection or infusion Infusion rate (micrograms/kg/min) Patient body weight (kg) 10 20 30 40 50 60 70 80 90 100 0.0125 0.3 0.6 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3.0 0.025 0.6 1.2 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 0.05 1.2 2.4 3.6 4.8 6.0 7.2 8.4 9.6 10.8 12.0 0.075 1.8 3.6 5.4 7.2 9.0 10.8 12.6 14.4 16.2 18.0 0.1 2.4 4.8 7.2 9.6 12.0 14.4 16.8 19.2 21.6 24.0 0.15 3.6 7.2 10.8 14.4 18.0 21.6 25.2 28.8 32.4 36.0 0.2 4.8 9.6 14.4 19.2 24.0 28.8 33.6 38.4 43.2 48.0 Table 4. Infusion rates (mL/h) for a solution of 50 micrograms/mL of Remifentanil Noridem powder for concentrate for solution for injection or infusion Infusion rate (micrograms/kg/min) Patient body weight (kg) 30 40 50 60 70 80 90 100 0.025 0.9 1.2 1.5 1.8 2.1 2.4 2.7 3.0 0.05 1.8 2.4 3.0 3.6 4.2 4.8 5.4 6.0 0.075 2.7 3.6 4.5 5.4 6.3 7.2 8.1 9.0 0.1 3.6 4.8 6.0 7.2 8.4 9.6 10.8 12.0 0.15 5.4 7.2 9.0 10.8 12.6 14.4 16.2 18.0 0.2 7.2 9.6 12.0 14.4 16.8 19.2 21.6 24.0 0.25 9.0 12.0 15.0 18.0 21.0 24.0 27.0 30.0 0.5 18.0 24.0 30.0 36.0 42.0 48.0 54.0 60.0 0.75 27.0 36.0 45.0 54.0 63.0 72.0 81.0 90.0 1.0 36.0 48.0 60.0 72.0 84.0 96.0 108.0 120.0 1.25 45.0 60.0 75.0 90.0 105.0 120.0 135.0 150.0 1.5 54.0 72.0 90.0 108.0 126.0 144.0 162.0 180.0 1.75 63.0 84.0 105.0 126.0 147.0 168.0 189.0 210.0 2.0 72.0 96.0 Країна реєстрації Spain Активна речовина Remifentanilo hidrocloruro Потрібен рецепт Так Виробник Noridem Enterprises Limited Информация носит справочный характер и не является медицинской рекомендацией. Перед приёмом любых препаратов проконсультируйтесь с врачом. Oladoctor не несёт ответственности за медицинские решения, принятые на основе этого контента. Поговоріть з лікарем онлайн Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду. 5.01 відгук Anna Moret Dermatology18 років досвіду Dr. Anna Moret is a board-certified dermatologist and dermatovenereologist. She specialises in adult and pediatric dermatology, venereology, aesthetic skin care, and general medicine. Her consultations are evidence-based and tailored to each patient’s dermatological needs. Dr. Moret provides expert evaluation and treatment for: • Skin conditions such as eczema, acne, rosacea, dermatitis, and psoriasis • Hair and scalp issues including hair loss, dandruff, and seborrheic dermatitis • Pediatric skin problems — from newborns to adolescents • Sexually transmitted infections (STIs) and dermatovenereology • Aesthetic concerns: skin ageing, non-invasive cosmetic treatments • Skin allergies and hypersensitivity reactions • Mole checks, lesion evaluation, and skin cancer screening • Skincare advice and personalised cosmeceutical routines Combining dermatology with general medical knowledge, Dr. Moret offers comprehensive care that addresses both skin health and underlying conditions. She also holds certification from the Canadian Board of Aesthetic Medicine, ensuring an internationally aligned approach to aesthetic dermatology. Записатися на онлайн-консультацію Більше часу 5.01 відгук Alina Tsurkan Family Medicine12 років досвіду Dr. Alina Tsurkan is a licensed family medicine doctor based in Portugal. She provides personalised primary care for both adults and children, helping patients manage a wide range of everyday health concerns with professionalism and attention to detail. Dr. Tsurkan diagnoses and treats common conditions such as: • Respiratory infections (cold, flu, bronchitis, pneumonia) • Eye conditions: conjunctivitis (infectious and allergic) • ENT problems (sinusitis, ear infections, tonsillitis) • Digestive issues including gastritis, acid reflux, and IBS • Urinary tract infections and other frequent infections • Chronic conditions such as high blood pressure, diabetes, and thyroid disorders • Headaches and migraines In addition to symptom-based care, Dr. Tsurkan focuses on prevention and early detection. She offers regular health check-ups, follow-up care, and medical prescriptions tailored to each patient’s needs. With a comprehensive and caring approach, Dr. Tsurkan supports patients at every stage of life — from acute illnesses to long-term health management. Записатися на онлайн-консультацію Більше часу 5.09 відгуків Andrei Popov General Medicine6 років досвіду Dr. Andrei Popov is a licensed pain management specialist and general practitioner based in Spain. He provides expert online care for adults dealing with both chronic and acute pain, as well as a wide range of everyday health concerns. He specialises in diagnosing and treating pain conditions that affect quality of life, including: • Chronic pain lasting more than 3 months • Migraines and recurring headaches • Neck, back, lower back, and joint pain • Post-traumatic pain following injury or surgery • Nerve-related pain, fibromyalgia, and neuralgia In addition to pain management, Dr. Popov helps patients with: • Respiratory infections (colds, bronchitis, pneumonia) • High blood pressure and metabolic conditions such as diabetes • Preventive care and routine health check-ups Online consultations last up to 30 minutes and include a detailed symptom review, personalised treatment planning, and medical follow-up when needed. Dr. Popov’s approach is rooted in evidence-based medicine, combined with individualised care tailored to each patient’s history, lifestyle, and clinical needs. Записатися на онлайн-консультацію Більше часу 5.01 відгук Yevgen Yakovenko General Surgery11 років досвіду Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain, with a diverse clinical background in general and pediatric surgery, internal medicine, and pain management. With a strong focus on both practice and research, he provides comprehensive medical consultations for adults and children, covering both surgical and therapeutic needs. Dr. Yakovenko offers expert care in the following areas: • Diagnosis and treatment of acute and chronic pain • Pre- and postoperative care, including risk assessment and follow-up • Surgical conditions such as hernias, gallbladder disease, and appendicitis • Pediatric surgery consultations, including congenital conditions and minor procedures • Trauma care: fractures, soft tissue injuries, and wound management • Oncological surgery consultation and post-treatment care • Cardiovascular and respiratory conditions (internal medicine) • Orthopedic concerns and post-trauma rehabilitation • Radiological interpretation for surgical planning In addition to his clinical work, Dr. Yakovenko actively participates in medical research and international collaboration. He is a member of the German Surgeons Association (BDC), affiliated with the General Practitioners Association of Las Palmas, and works with the German Consulate in the Canary Islands. He regularly attends international medical conferences and has authored scientific publications. With over a decade of multidisciplinary experience, Dr. Yakovenko delivers precise, evidence-based care tailored to each patient’s needs. Записатися на онлайн-консультацію Більше часу Переглянути всіх лікарів Слідкуйте за новинами та заощаджуйте на послугах Поради лікарів, оновлення платформи та знижки для підписників. Підписатися Слідкуйте за нами в соцмережах ПослугиЛікаріДопомога Пошук